eGenesis, Inc.’s Post

Thanks to Between the Biotech Waves podcast host Nessan Bermingham, partner at Khosla Ventures for speaking with our President & CEO Michael Curtis about our work at eGenesis to develop porcine donors for human tissue transplant. 🧬🧬 Mike has a 25 year plus history in biotech from Infinity to Cadent where he played a critical role in the merger of Ataxion Therapeutics with Luc to Catabasis where he led product development and regulatory affairs to his current role as CEO and President at eGenesis. Tune in and listen to his journey! 👇👇 https://lnkd.in/esyhiiWG

Our Chief Business Officer Jennifer Bergheiser spoke on a panel at #BIO2024 last week in San Diego on Increasing Healthspan, moderated by Hilary Brueck, health correspondent at Business Insider. Great to see everyone and looking forward to the next event! 🧬🧬🧬

Our Chief Business Officer Jennifer Bergheiser will be on a panel at #BIO2024 this week in San Diego on the topic of increasing healthspan. 🧬🧬🧬 The panel is moderated by Hilary Brueck, health correspondent at Business Insider, featuring executives from Rejuvenate Bio, Fauna Bio, Strand Therapeutics and Moonwalk Biosciences. More info here: 👇👇👇 https://lnkd.in/eiUbyfym

We're proud to be included on TIME's list of the 100 Most Influential Companies of 2024! The TIME100 Most Influential Companies list highlights companies making an extraordinary impact around the world.  #TIME100Companies Thanks Alice Park at TIME for following our journey all these years, and speaking with our CEO Michael Curtis about the impact our organs has on the current transplant shortage: "Science fiction became reality this year when the first human patient received a pig-kidney transplant from eGenesis, a company that genetically engineers pigs to make their organs less porcine and more human for transplantation. Although the patient died months later from unrelated issues, the transplant could be the start of a new source of organs to address a critical shortage. CEO Mike Curtis plans to ask the U.S. FDA to greenlight the next patient, expand the number of animals it breeds, and work on transplanting other organs, including the liver, this year. Questions still swirl about how long the transplants will last in humans, and how exactly they need to be tweaked, but for now, the pig organs are buying patients precious time and could help many live healthier lives." To assemble the list, TIME solicited nominations across sectors, and polled its global network of contributors and correspondents, as well as outside experts. Then TIME editors evaluated each on key factors, including impact, innovation, ambition, and success. The result is a diverse group of 100 businesses helping chart an essential path forward.  Read the article on eGenesis: https://lnkd.in/dRJawBsT View the full list of 100 companies: https://lnkd.in/gbBdS4m5

NPR 1A podcast invited our CEO Michael Curtis to join a discussion to discuss the current state of #kidney transplantation and what the future might look like. Panelists: Syd Johnson bioethicist, SUNY Upstate Medical University; clinical ethics consultant Dr. Tatsuo Kawai director, Legorreta Center for Clinical Transplant Tolerance; chair in transplant surgery, Massachusetts General Hospital Mike Curtis CEO and president, eGenesis Dr. Sylvia Rosas president, National Kidney Foundation; nephrologist, Joslin Diabetes Center in Boston Listen to the podcast: https://lnkd.in/enxrUNe3

We are saddened by the passing of Mr. Rick Slayman and extend our deepest condolences to his family and loved ones. Mr. Slayman was a true pioneer – his courage has helped to forge a path forward for current and future patients suffering from kidney failure. We are profoundly grateful to Mr. Slayman and his family and we will honor his legacy and invaluable contribution to science and medicine by continuing our efforts to advance xenotransplantation for the millions of patients globally in need of lifesaving organs. https://lnkd.in/eH_TNzHk